New cancer drug enters first human trials
NCT ID NCT07165067
Summary
This is the first human study of an experimental cancer drug called AP601. Researchers are testing it in 36 patients with advanced solid tumors to find the highest dose that can be given safely. The study will carefully monitor patients for side effects while gathering initial information about how the drug behaves in the body and whether it shows any signs of fighting cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOURS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Calvary Mater Newcastle
NOT_YET_RECRUITINGWaratah, New South Wales, 2298, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Epworth HealthCare
RECRUITINGMelbourne, Victoria, 3121, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pindara Private Hospital
NOT_YET_RECRUITINGBrisbane, Queensland, 4217, Australia
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.